bioMérieux offers a comprehensive range of diagnostic tools to support COVID-19 patient care
COVID-19 may lead to respiratory failure in some patients, often associated with serious complications such as Acute Kidney Injury (AKI) or Sepsis.
From primary diagnosis of SARS-CoV-2 to patient discharge, bioMérieux supports you at every step*:
Primary Diagnosis
 |
Real-time Polymerase Chain Reaction (PCR) technology to specifically detect the coronavirus responsible for the COVID-19 pandemic |
 |
Uses a syndromic approach to accurately detect and identify 23 clinically relevant viral and bacterial targets most commonly associated with respiratory infections, including SARS-CoV-2. With a run time of about 45 minutes, the RP2.1plus Panel may enable better-informed diagnosis and treatment of patients. |
 |
Measure the presence of antibodies in less than 30 minutes in people who have been infected with SARS-CoV-2 One semi quantitative assay for the detection of specific immune response and quantification of the level of anti-SARS-CoV-2 IgG antibodies |
 |
Severity Assessment
 |
|
 |
Acute Kidney Injury biomarker |
Identify potential co-infections and secondary infections
 |
Specific biomarker of severe bacterial infection and Sepsis |
 |
Family of automated microbial detection systems and blood culture media |
 |
The BioFire PNplus Panel tests for 34 clinically relevant targets, including bacteria, viruses, and antimicrobial resistance genes—all with one test and with results available in about an hour. The BioFire BCID2 Panel tests for 43 clinically relevant targets, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes—all with one test and with results available in about an hour from positive blood culture.
|
 |
Automated Gram staining |
 |
Mass spectrometry for identification of pathogens |
 |
A range of real-time PCR kits for accurate simultaneous detection of infectious agents involved in respiratory diseases |
 |
|
 |
Chromogenic media for growth and identification of pathogens |
 |
Microbial identification and Antimicrobial susceptibility testing |
Antimicrobial treatment Selection and monitoring
For potential co-infections and secondary infections
 |
Specific biomarker of severe bacterial infection and sepsis |
|
Microbial identification and Antimicrobial susceptibility testing |
 |
MIC for critical cases |
Outcome assessment/ discharge / follow-up
| |
Measure the presence of antibodies in less than 30 minutes in people who have been infected with SARS-CoV-2 |
 |
Real-time Polymerase Chain Reaction (PCR) technology to specifically detect the coronavirus responsible for the COVID-19 pandemic |
 |
* Availability of the product range is subject to local regulatory approvals, allocation priorities, supply chain policies, etc. Please check availability with your local bioMérieux representative.
Explore the COVID-19 bioMérieux solutions page on biomerieux-diagnostic.com